AACR 2022 | Targeting the N-myristoylation pathway to treat adult acute myeloid leukemia
Naveen Pemmaraju
• 11 Apr 2022
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses how the N-myristoylation pathway can be targeted as a new therapy for adult acute myeloid leukemia (AML). Pre-clinical models have shown that this pathway is overexpressed in patients with AML and can be targeted with the novel oral agent PCLX-001. PCLX-001 shall now undergo clinical investigation in patients with relapsed/refractory AML. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
